Hologic Inc. (HOLX)
Hologic's Diagnostics Arm Set for Long-Term Upside: What's Behind It?
HOLX's Diagnostics arm eyes long-term growth with new assays, platform expansion and oncology test adoption despite headwinds.
Should You Buy, Sell or Hold Hologic Stock Post Q3 Earnings?
HOLX rises post earnings beat, fueled by Diagnostics strength and Surgical growth. However, macro headwinds persist.
Why Hologic (HOLX) is a Top Value Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Interpreting Hologic (HOLX) International Revenue Trends
Evaluate Hologic's (HOLX) reliance on international revenue to better understand the company's financial stability, growth prospects and potential stock price performance.
Hologic, Inc. (HOLX) is Attracting Investor Attention: Here is What You Should Know
Hologic (HOLX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Hologic Stock Falls Despite Q3 Earnings and Revenue Beat, Margins Down
HOLX posts better-than-expected Q3 results, but margin contraction and regional headwinds pressure investor sentiment.
Hologic, Inc. (HOLX) Q3 2025 Earnings Call Transcript
Hologic, Inc. (NASDAQ:HOLX ) Q3 2025 Earnings Conference Call July 30, 2025 4:30 PM ET Company Participants Essex D. Mitchell - Chief Operating Officer Karleen M.
Compared to Estimates, Hologic (HOLX) Q3 Earnings: A Look at Key Metrics
The headline numbers for Hologic (HOLX) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Hologic (HOLX) Q3 Earnings and Revenues Beat Estimates
Hologic (HOLX) came out with quarterly earnings of $1.08 per share, beating the Zacks Consensus Estimate of $1.05 per share. This compares to earnings of $1.06 per share a year ago.
Hologic Focuses on Breast Health Turnaround This Year: Can It Deliver?
HOLX eyes a Breast Health rebound in Q4, backed by leadership changes, new strategy and Endomag momentum.
Seeking Clues to Hologic (HOLX) Q3 Earnings? A Peek Into Wall Street Projections for Key Metrics
Get a deeper insight into the potential performance of Hologic (HOLX) for the quarter ended June 2025 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of its key metrics.
HOLX vs. EXAS: Which Cancer Diagnostics Stock Should You Retain Now?
EXAS gains edge over HOLX as rising Cologuard adoption, new launches and bullish EPS trends boost investor appeal.
